U.S. National Library of MedicineNational Institutes of Health
Skip navigation
MedlinePlus Trusted Health Information for You MedlinePlus Trusted Health Information for You MedlinePlus Trusted Health Information for You
  FAQs Site Map About MedelinePlus Contact Us
español
Reuters Health Information Logo

Antibody useful for psoriasis-related arthritis

Printer-friendly version E-mail this page to a friend

Reuters Health

Wednesday, February 18, 2009

NEW YORK (Reuters Health) - Treatment with ustekinumab, an antibody that attacks certain cell messenger chemicals, can reduce the signs and symptoms of psoriasis-related arthritis. The treatment is also well tolerated by patients, according to a report in The Lancet, a prominent British medical journal.

Psoriasis is a condition linked to an overactive immune system that causes inflamed, scaly red patches to form on the elbows, knees, scalp and trunk. In some cases, psoriasis causes arthritis symptoms, such as swollen, stiff, or painful joints.

Dr. Alice Gottlieb, from Tufts Medical, Boston, and colleagues note that there is a need for drugs to treat psoriatic arthritis when standard treatments fail.

Prior research has suggested that cell messenger proteins, called interleukin 12 and interleukin 23, play a role in the symptoms and joint damage seen in patients with psoriatic arthritis, the authors explain, and thus treatment with an agent that blocks these proteins may have a beneficial effect.

The current trial involved 146 patients who were randomly assigned to receive ustekinumab or an inactive "placebo" for several weeks.

At 12-week follow-up, 42 percent of ustekinumab-treated patients showed a meaningful improvement in symptoms compared with 14 percent of those given placebo.

Among 124 subjects with psoriasis affecting 3 percent or more of their body surface area, 52 percent of ustekinumab-treated patients and just 5 percent of those given placebo showed a 75 percent or greater improvement in psoriasis severity and a reduction of the affected area.

Side effects with ustekinumab were no more likely than with placebo and no serious complications were noted with the drug.

The effectiveness of "ustekinumab for improving skin and joint involvement, which was maintained for several months, combined with good tolerability and a benign safety profile, make this agent an attractive option in psoriatic arthritis," Dr. Raquel S. Cuchacovich and Dr. Luis R. Espinoza, from Louisiana State University Health Sciences Center, New Orleans, comment in a related editorial.

SOURCE: The Lancet, February 12th online, 2009.


Reuters Health

Copyright © 2009 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

Related News:
More News on this Date

Related MedlinePlus Pages: